Rani Therapeutics
RANI
74 hedge funds and large institutions have $31.3M invested in Rani Therapeutics in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 8 closing their positions.
9,917% more call options, than puts
Call options by funds: $3.51M | Put options by funds: $35K
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
16% more funds holding
Funds holding: 64 → 74 (+10)
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.09% less ownership
Funds ownership: 45.95% → 42.86% (-3.1%)
48% less capital invested
Capital invested by funds: $60.5M → $31.3M (-$29.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$310K |
| 2 |
LP
Longaeva Partners
Chicago,
Illinois
|
+$276K |
| 3 |
Jane Street
New York
|
+$212K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$196K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$168K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCP
SymBiosis Capital Partners
Bentonville,
Arkansas
|
-$3.36M |
| 2 |
Squarepoint
New York
|
-$419K |
| 3 |
Goldman Sachs
New York
|
-$350K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$129K |
| 5 |
VF
Virtu Financial
New York
|
-$69K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Bank of America
Charlotte,
North Carolina
| – | -$49.4K | -36,607 | Closed |
|
|
TSS
77
Two Sigma Securities
New York
| – | -$48.4K | -35,874 | Closed |
|
|
SOW
78
State of Wyoming
Cheyenne,
Wyoming
| – | -$2.8K | -2,076 | Closed |
|
79
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.35K | -1,000 | Closed |
|
|
EW
80
Elyxium Wealth
San Mateo,
California
| – | -$1.03K | -760 | Closed |
|
81
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$6 | +5 | +4% |
|
RANI Hedge Fund Activity: Q1 2026 in Review
74 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q1 2026, worth a combined $31.3M — down 48% from $60.5M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RANI positions and 8 closed out — a net gain of 11 holders — while 16 added to existing stakes and 14 trimmed.
The largest buyer was Millennium Management, adding an estimated $310K. The largest seller was SymBiosis Capital Partners, cutting an estimated $3.36M.
- 74 institutional investors held Rani Therapeutics (RANI) as of Q1 2026, up from 64 in Q4 2025.
- Funds reported $31.3M of Rani Therapeutics stock for Q1 2026, down 48% quarter-over-quarter.
- 19 funds opened new Rani Therapeutics positions in Q1 2026 and 8 closed out, a net change of +11 holders.
- The largest Rani Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $310K added.
- The largest Rani Therapeutics seller in Q1 2026 was SymBiosis Capital Partners, an estimated $3.36M sold.
Based on aggregated 13F filings for Q1 2026.